Announcement on Voluntary Disclosure of GB19 Injection Obtaining FDA Clinical Trial Approval for New Drugs

About this update from Kexing Biopharm Co., Ltd. Class A

Announcement on Voluntary Disclosure of GB19 Injection Obtaining FDA Clinical Trial Approval for New Drugs The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Kexing Biopharm Co., Ltd. Class A